Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > It does not make a lot of sense

<< Previous

Bullboard Posts

Next >>

Comment by mstrmndson Mar 26, 2024 2:55pm

306 Views

Post# 35953666

RE:It does not make a lot of sense

Because it's not up to Nuance to decide. The payment terms are not in Nuance's control and is subject to fair negotiation. Antibe controls the cash and can drag out repayment until more favourable for the company. Antibe needs an MOU to delay repayment that can be publicly disclosed while the payment terms are negotiated longitudinally.

Bottom line, a creditor cannot impose repayment due to percieved risks of failure when Antibe has control.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 29, 2024